CNASHighly Regulated (List I)CEFALIZOL HUP
HUPP
Identification
- Active ingredient (INN)
- CAFAZOLINE SOUS FORME DE CEFAZOLINE SODIQUE
- Internal code
- 13 B 012
- Country of Origin
- Algeria
- Pharmaceutical form
- Powder + Solvent for IV/IM Injectable Sol.
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/1 flacon de poudre et une ampoule de solvant et b/10 flacons de poudre
CNASDAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis.
It attains high serum levels and is excreted quickly via the urine.
Indications
Mainly used to treat bacterial infections of the skin.
It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract.
It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria.
May be used for surgical prophylaxis; if required metronidazole may be added to cover B. fragilis.
Pharmacodynamics
Cefazolin (also known as cefazoline or cephazolin) is a semi-synthetic first generation cephalosporin for parenteral administration.
Cefazolin has broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis.
It attains high serum levels and is excreted quickly via the urine.
Mechanism of Action
Penicillin-binding protein 1A (Escherichia coli (strain K12)) Inhibitor Penicillin-binding protein 1B (Escherichia coli (strain K12)) Inhibitor Penicillin-binding protein 1C (Escherichia coli (strain K12)) Inhibitor + 2 more targets.
Absorption
Not absorbed from
GI tract.
Must be administered parenterally.
Peak serum concentrations attained 1-2 hours post intramuscular injection.
Route of Elimination
Cefazolin is present in very low concentrations in the milk of nursing mothers.
Cefazolin is excreted unchanged in the urine.
In the first six hours approximately 60% of the drug is excreted in the urine and this increases to 70%-80% within 24 hours.
Half-life
The serum half-life is approximately 1.8 hours following Intravenous administration and approximately 2.0 hours following Intramuscular administration.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.